Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
To compare the lipidomic profile in patients with HIV-1 with viral suppression changing
efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir
(Eviplera®) versus a group of patients that continue with Atripla®.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Collaborator:
Gilead Sciences
Treatments:
Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Tenofovir